Cuscuta reflexa (C. reflexa) Roxb. (Convolvulaceae) has medicinal properties for the effective management of several aliments including diabetes mellitus, inflammation, and gastric ulcer. The present investigation focuses on the antidiabetic potential of C. reflexa leaves methanol extract in alloxan-induced diabetic rats. The antidiabetic activity of C. reflexa leaves methanol extract (CRME) was evaluated using alloxan-induced diabetes in Wistar albino rats. The duration of the study was 45 days. Diabetic model was developed by i.p. administration of alloxan monohydrate (120 mg/kg). Ingestion of CRME (100, 200, and 400 mg/kg/day) and standard (gliclazide, 10 mg/kg/day) was done via oral route from the day of diabetes induction and continued up to 45 days. The effect of CRME was investigated by evaluating the blood glucose concentrations, HbA1C, insulin, lipid profile and liver function test. Further, the protective potentials of CRME were studied by histopathology of the pancreas, liver, and kidney tissues from experimental rats. CRME showed significant (p < 0.01 at all doses) reduction of blood glucose level (137.1 ± 5.8, 125.9 ± 6.5, and 109.5 ± 5.4 mg/dL at the doses of 100, 200, and 400 mg/kg, respectively) as compared to the diabetic control (249.7 ± 7.3 mg/dL). Moreover, CRME at the highest dose decreased HbA1C and improved insulin levels (3.96% and 11 ng/ml, respectively) when compared with diabetic control group (7.55% and 6.5 ng/ml, respectively). CRME also revealed pronounced improvement in liver function test and lipid profile test when compared to the diabetic control. Furthermore, CRME notably reversed the histopathological changes that observed in alloxan-induced diabetes. Our research exertion clearly demonstrates that CRME can be explored as a substantial antidiabetic and organ protective agent in the management of diabetes.

中文翻译：

---

看好的anitidiabetic潜在菟丝子reflexa叶甲醇提取物对四氧嘧啶诱导的糖尿病大鼠

Cuscuta reflexa（C. reflexa）Roxb。（旋花科）具有有效治疗多种饮食的药物特性，包括糖尿病，炎症和胃溃疡。本研究侧重于四氧嘧啶诱导的糖尿病大鼠反射小球藻叶甲醇提取物的抗糖尿病潜力。使用四氧嘧啶诱导的糖尿病大鼠Wistar albino评价了反射小球藻叶甲醇提取物（CRME）的抗糖尿病活性。研究持续时间为45天。通过腹膜内注射四氧嘧啶一水合物（120 mg / kg）建立糖尿病模型。从诱导糖尿病的那一天开始，通过口服途径摄入CRME（100、200和400 mg / kg /天）和标准品（格列齐特，10 mg / kg /天），并持续45天。通过评估血糖浓度HbA1C来研究CRME的效果，胰岛素，血脂和肝功能检查。此外，通过对实验大鼠的胰腺，肝脏和肾脏组织进行组织病理学研究，研究了CRME的保护潜力。与之相比，CRME显示出显着（在所有剂量下p <0.01）降低血糖水平（分别在100、200和400 mg / kg剂量下分别降低137.1±5.8、125.9±6.5和109.5±5.4 mg / dL）糖尿病对照（249.7±7.3 mg / dL）。此外，与糖尿病对照组（分别为7.55％和6.5 ng / ml）相比，最高剂量的CRME降低了HbA1C，改善了胰岛素水平（分别为3.96％和11 ng / ml）。与糖尿病对照相比，CRME还显示出肝功能测试和血脂测试的显着改善。此外，CRME显着逆转了四氧嘧啶诱发的糖尿病中观察到的组织病理学变化。我们的研究成果清楚地表明CRME可以作为糖尿病的重要抗糖尿病和器官保护剂而被开发。